Bangladesh antirheumatic drugs market was valued at US$1,953.071 million in 2019. Increasing cases of rheumatoid arthritis in Bangladesh is one of the major factors that is fuelling the market growth of antirheumatic drugs in the country. Another major driver is the prevalence of malaria in Bangladesh which is a significant public health problem in the country. Increasing burden of chronic diseases coupled with growing geriatric population is further boosting the demand for antirheumatic drugs in this country. Since the country suffers from the shortage of healthcare workers and lacks proper healthcare infrastructure, people are opting for over-the-counter drugs to treat various chronic diseases including arthritis, thereby driving the market growth of antirheumatic drugs in the country. However, factors such as low healthcare service coverage, unregulated healthcare system, and underfunding of the health financing are restraining the market growth of antirheumatic drugs in Bangladesh.
Bangladesh Antirheumatic Drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis,rheumatoid arthritis, gout, lupus, and others. By type of molecule, Bangladesh Antirheumatic Drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).